EU approves Xgeva and throws Amgen a bone - one year's extra protection
This article was originally published in Scrip
Executive Summary
The European Commission has approved Amgen's RANK ligand inhibitor Xgeva (denosumab) for the prevention of skeletal-related events (SREs) in adults with bone metastases from solid tumours.